Sponsored Links
Industry Analysis
Frequently Updated Stats, Analysis & Forecasts. Over 700 Industries.
Healthcare Industry
Find Training in Los Angeles Area. See Career, Salary, Industry Info.
Novartis Deal Gives Incyte a Boost
Blog | seekingalpha.com | 5 hours 51 minutes ago
EP Vantage submits:As only the second JAK inhibitor to enter phase III trials, Incytes (INCY) INCB18424 has already attracted a fair amount
http://seekingalpha.com/article/175325-novartis-deal-gives-incyte-a-boost?source=feed
Pfizer, Spanning the Globe to Defend Lipitor Patents (at The Wall Street Journal Online)
Blog | blogs.wsj.com | 6 hours 9 minutes ago
Emerging markets may be essential to the growth of the global drug industry, but that doesn't mean growth comes easily in the developing world.
Has a new day dawned for medicinal cannabis?
Blog | www.genengnews.com | Nov 23, 2009
Marijuana. It’s a small word that generates a large reaction (for better or for worse). People are polarized on the topic. Yes, there is a definite social stigma surrounding this infamous, leafy pl
Merck: We're Number Two (at Barrons.com)
Blog | blogs.barrons.com | Nov 4, 2009
Merck (MRK) re-asserted its claim on the place in the drug-maker firmament that it held down a decade ago, as it closed its deal to acquire Schering-Plough and moved into second place among drug companies, measured by sales.
http://blogs.barrons.com/stockstowatchtoday/2009/11/04/merck-were-number-two/?mod=yahoobarrons
Stuart Laidlaw is Going to Get Me [a] Shot from Merck
Blog | blog.bioethics.net | Jun 16, 2009
I couldn't be more pleased that [insert gratuitous but sincere praise:] outstanding Toronto Star writer Stuart Laidlaw has been rigorously following the Merck/Elsevier scandal. It's practically flattering that he's listening to bioethics' and in particular bioethics' publishing voices, and he's...
http://blog.bioethics.net/2009/06/stuart-laidlaw-is-going-to-get-me-a-shot-from-merc/
Pfizer Pfizzle (at Fortune)
Blog | postcards.blogs.fortune.cnn.com | Jun 23, 2008
It’s remarkable to see Pfizer (PFE) stock trading below 18. That’s a price level unseen since 1997. When CEO Jeff Kindler (formerly of McDonalds (MCD)) came by Fortune recently, he fielded questions about the business' well-known challenges: expiring patents, pipeline deficiencies, slow new-product
http://postcards.blogs.fortune.cnn.com/2008/06/23/pfizer-pfizzle/?source=yahoo_quote
Merck overturns one Vioxx verdict, slashes another (at Fortune)
Blog | legalpad.blogs.fortune.cnn.com | May 29, 2008
Merck, the giant pharmaceutical maker, scored two major victories Thursday in its ongoing defense of lawsuits stemming from its Vioxx painkiller. A Texas appeals court overturned one verdict and a New Jersey appeals court partially overturned another. In all, more than $35 million in damages was
Schering-Plough slumps again (at Fortune)
Blog | dailybriefing.blogs.fortune.cnn.com | Mar 31, 2008
Update: It's open season on Schering-Plough (SGP). Shares of the drug company plunged 26% in early morning action Monday to a 52-week low after another big setback for Vytorin, the cholesterol drug the company makes with partner Merck (MRK). A panel of heart doctors at the American College of
Talk to Me: Consolidation beat goes on
The consolidation rage continues. This time it is happening in the pharmaceutical industry. Just when will consolidation end? Are there more rounds to go? Germany’s Merck made a huge move to pick up Schering today. Merck is looking at paying $17.4 billion for its fellow German drug maker.
http://www.isa.org/intech/blog/2006/03/consolidation-beat-goes-on.html
Research and Discovery | Health Commentary
...Healthy Voices represents all places, races, genders, ages, socio-economic status and occupations -- and it will inform, instruct and ignite a debate on the status of our current health care system and what should be done to improve it...
http://healthcommentary.org/public/blog/182421?archive=Monthly+*none
